Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

NCT00742963 is registered in ClinicalTrials.gov with ImmunoGenesis as lead sponsor.

NCT NCT00742963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00742963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Lead sponsor
ImmunoGenesis
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2008
Completion date
October 31, 2013
Enrollment
107 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma